Clinical trials: Gliomas, Malignant
Oligodendroglioma, Astrocytoma
First in Patient Study for PF-06840003 in Malignant Gliomas
This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.
- Conditions
- Oligodendroglioma, Astrocytoma, Malignant Glioma
- Trial name
- NCT02764151
- Testing
- PF-06840003
- Where
- 14 sites in United States
- Volunteers
- 17 people
- Sponsor
- Pfizer
Glioma, Glioblastoma
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2 used as a tool to disrupt the BBB (blood brain barrier) in patients with high grade glioma undergoing standard of care therapy.
- Trial name
- NCT03551249
- Testing
- Focused ultrasound (FUS)
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- InSightec
Glioma
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive…
- Trial name
- NCT01906385
- Testing
- Rhenium Liposome Treatment
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Cerenome
Malignant Glioma
Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
The objective of this study is to determine the survival status of patients enrolled in study GLI01S (all-case observational study).
- Trial name
- NCT02300506
- Testing
- No intervention
- Where
- 2 sites in Japan
- Volunteers
- 507 people
- Sponsor
- Eisai Co., Ltd.
Recurrent and Refractory Solid Tumors
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Phase 1 of this study, utilizing a rolling 6 design, will be conducted to determine a maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), and to describe the toxicities of lenvatinib administered in combination with…
- Trial name
- NCT03245151
- Testing
- Lenvatinib, Everolimus
- Where
- 50 sites in United States, Canada
- Volunteers
- 64 people
- Sponsor
- Eisai Inc.
Malignant Glioma, Glioblastoma Multiforme
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.
- Trial name
- NCT02590263
- Testing
- Whole Brain Radiation, Temozolomide, ABT-414
- Where
- 22 sites in Japan
- Volunteers
- 53 people
- Sponsor
- AbbVie
Glioblastoma Multiforme, Glioma
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly…
- Conditions
- Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
- Trial name
- NCT02052648
- Testing
- Indoximod, Temozolomide, Bevacizumab
- Where
- 17 sites in United States
- Volunteers
- 160 people
- Sponsor
- NewLink Genetics Corporation
Brain Edema, Brain Tumor
XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema
The purpose of this study is to examine the safety and efficacy of XERECEPT (human Corticotropin-Releasing Factor, or hCRF) compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone…
- Trial name
- NCT00226668
- Testing
- hCRF
- Where
- 26 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Celtic Pharma Development Services
Malignant Glioma, Glioblastoma Multiforme
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
The purpose of this study is to evaluate the safety and effectiveness of 131I-TM601 in the treatment of adult patients with progressive or recurrent malignant gliomas.
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma
- Trial name
- NCT00683761
- Testing
- 131I-TM601
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- TransMolecular
High Grade Glioma
Nimotuzumab in Children With HGG
Determination of efficiency of nimotuzumab in children with high grade glioma.
- Trial name
- NCT00561873
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Oncoscience AG
Diffuse Astrocytoma, Anaplastic Astrocytoma
Pediatric Long-Term Follow-up and Rollover Study
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
- Conditions
- Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
- Trial name
- NCT03975829
- Testing
- dabrafenib, trametinib
- Where
- 54 sites in United States, Argentina and 17 more
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals
Glioma
Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
Clinical study of a novel oncolytic virus Ad-TD-nsIL12 in the treatment of primary high-grade glioma
- Trial name
- NCT07126990
- Testing
- Novel oncolytic virus Ad-TD-nsIL12
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiaorong Wu
High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
This study is researching an experimental drug called cemiplimab (called "study drug") and the combination of experimental drugs of fianlimab and cemiplimab (called "study drugs").
- Trial name
- NCT07567469
- Testing
- Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC)
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Glioma, Malignant
Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
The purpose of this trail is to evaluate the performance of Genetron TERT PCR Kit in Glioma patients using real-time PCR method.
- Trial name
- NCT05100602
- Where
- 4 sites in China
- Volunteers
- 1,192 people
- Sponsor
- Genetron Health
Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
The purpose of this study is to determine the safety, tolerability, and the maximum tolerated dose/recommended phase II dose of carboxyamidotriazole orotate (CTO) as a single agent in patients with advanced or metastatic solid…
- Trial name
- NCT01107522
- Testing
- CTO, CTO and Temodar®, CTO, Temodar®, Radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Tactical Therapeutics, Inc.
Newly Diagnosed High Grade Glioma (HGG)
A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care
This is a multi-center, open label trial of combination therapy with Toca 511 and ascending doses of Toca FC added to the SOC for newly diagnosed HGG.
- Trial name
- Toca7 (NCT02598011)
- Testing
- Toca 511, Toca FC
- Sponsor
- Tocagen Inc.
Glioma, Malignant, Computer-Assisted Surgery
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
The aim of this observational study is to enable rapid diagnosis of molecular biomarkers in patients during surgery by medical imaging and artificial intelligence models, to help clinicians with strategies to maximize safe…
- Trial name
- NCT05656053
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Mingge LLC
High-grade Glioma
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
The clinical protocol plans to preset three dose groups, namely 1×10⁷ cells per dose, 3×10⁷ cells per dose, and 6×10⁷ cells per dose.
- Trial name
- NCT06737146
- Testing
- MT027 cells suspension
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Suzhou Maximum Bio-tech Co., Ltd.
Malignant Glioma
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.
Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors.
- Trial name
- NCT00032903
- Testing
- Gimatecan® (ST 1481)
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sigma-Tau Research, Inc.